Concordance of butyrylcholinesterase phenotype with genotype: implications for biochemical reporting.

Butyrylcholinesterase (BChE) metabolizes the paralytic succinylcholine. Extended paralysis occurs in people with inherited BChE variants that may be identified by measuring BChE activity with and without the inhibitor dibucaine to calculate a dibucaine number (DN). Accurate phenotyping requires phenotype-specific BChE and DN reference intervals. We investigated the concordance between the biochemical BChE phenotype and the BCHE genotype to establish interpretive criteria for biochemical results. DNA was extracted from 45 serum specimens for which BChE activity and DN had been determined. The BCHE gene coding region was amplified and sequenced. Phenotype-genotype concordance and discordance occurred in 16 (36%) and 15 (33%) of specimens, respectively. A phenotype could not be assigned for 14 specimens (31%). An incorrectly assigned phenotype did not change the risk of prolonged paralysis or implied a slightly increased risk when there was none. Accurate BChE phenotyping is difficult using only enzyme activity and DN. The combination of biochemistry and BCHE genotype could improve the assessment of patient risk.

[1]  C. Iatrou,et al.  Anaesthetic implications of arrhythmogenic right ventricular dysplasia/cardiomyopathy , 2009, Anaesthesia.

[2]  M. Petzl-Erler,et al.  Two new mutations of the human BCHE gene (IVS3-14T>C and L574fsX576). , 2008, Chemico-biological interactions.

[3]  O. Lockridge,et al.  Five new naturally occurring mutations of the BCHE gene and frequencies of 12 butyrylcholinesterase alleles in a Brazilian population , 2008, Pharmacogenetics and genomics.

[4]  J. Bundgaard,et al.  Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia , 2007, Pharmacogenetics and genomics.

[5]  O. Lockridge,et al.  Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India , 2006, Pharmacogenetics and genomics.

[6]  R. Souza,et al.  Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample. , 2005, Molecular genetics and metabolism.

[7]  C. Lam,et al.  Novel mutations in the BCHE gene in patients with no butyrylcholinesterase activity. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[8]  D. Sullivan,et al.  Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. , 2003, Clinical chemistry.

[9]  F. Varin,et al.  Response to Mivacurium in a Patient Compound Heterozygous for a Novel and a Known Silent Mutation in the Butyrylcholinesterase Gene: Genotyping by Sequencing , 2001, Anesthesiology.

[10]  M. Maekawa,et al.  Genetic mutations of butyrylcholine esterase identified from phenotypic abnormalities in Japan. , 1997, Clinical chemistry.

[11]  B. La Du,et al.  Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase. , 1997, Pharmacogenetics.

[12]  C. Bartels,et al.  Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. , 1996, American journal of human genetics.

[13]  B. Du.  Butyrylcholinesterase variants and the new methods of molecular biology , 1995 .

[14]  C. P. Nogueira,et al.  Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. , 1992, American journal of human genetics.

[15]  C. Bartels,et al.  Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families. , 1992, Pharmacogenetics.

[16]  O. Lockridge,et al.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. , 1992, American journal of human genetics.

[17]  C. Bartels,et al.  DNA mutations associated with the human butyrylcholinesterase J-variant. , 1992, American journal of human genetics.

[18]  O. Lockridge,et al.  The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. , 1991, Genomics.

[19]  O. Lockridge.  Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. , 1990, Pharmacology & therapeutics.

[20]  C. P. Nogueira,et al.  Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Whittaker,et al.  E1h, a new allele at cholinesterase locus 1. , 1987, Human heredity.

[22]  A. Dietz,et al.  E1k, another quantitative variant at cholinesterase locus 1. , 1978, Journal of medical genetics.

[23]  P. Garry,et al.  E1j, a quantitative variant at cholinesterase locus 1: immunological evidence. , 1976, Journal of medical genetics.

[24]  J. King,et al.  A source of error in the determination of inhibitor constants of serum cholinesterase. , 1970, British journal of anaesthesia.

[25]  A. Szeinberg,et al.  A Silent Pseudocholinesterase Gene , 1965 .

[26]  D. Brown,et al.  A Pseudocholinesterase Variant in Human Tissues , 1963, Nature.

[27]  H. Harris,et al.  Differential Inhibition of Human Serum Cholinesterase with Fluoride: Recognition of Two New Phenotypes , 1961, Nature.

[28]  W. Kalow,et al.  On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. , 1957, Canadian journal of biochemistry and physiology.

[29]  W. Kalow,et al.  A METHOD FOR THE DETECTION OF ATYPICAL FORMS OF HUMAN SERUM CHOLINESTERASE. DETERMINATION OF DIBUCAINE NUMBERS , 1957 .